Loading...
Level 1 evidence supports the role of cisplatin-based neoadjuvant chemotherapy for patients undergoing cystectomy for muscle-invasive transitional cell cancer of the bladder. However, the use of adjuvant chemotherapy remains attractive to many clinicians given that patients are often referred following cystectomy.
To evaluate the effectiveness of adjuvant versus deferred cisplatin-based chemotherapy following cystectomy, European investigators conducted an intergroup, phase III, randomized, open-label study involving fit patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder. All patients underwent radical cystectomy and bilateral lymphadenectomy and within 90 days were randomized to receive either four cycles of adjuvant chemoth…